Biological evaluation of 10-(diphenylmethylene)- 4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione derivatives

Furse K.E., Lybrand T.P., Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists, J. Med. Chem., 2003, 46, 4450–4462 Kulig K., Sapa J., Maciąg D., Filipek B., Malawska B., Synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxypropyl]-pyrrolidin-2-one derivatives with anti-arrhythmic, hypotensive, and alpha-adrenolytic activity, Arch. Pharm. (Weinheim), 2007, 340, 466–475 Ferrarini P.L., Mori C., Badawneh M., Menera C., Saccomanni G., Calderone V., et al., Stereoselective synthesis and βblocking activity of substituted (E)-and (Z)-4(1H)-[1-(3-alkylamino-2-hydroxypropyl)oximino]-2,3-dihydro-1,8-naphthyridine. Potential anti-hypertensive agents. Part VI, Eur. J. Med. Chem., 1997, 32, 955–963 Bartošova L., Frydrych M., Hulakova G., Berankova K., Strnadova V., Mokry P., et al., Efficacy of newly synthesized 44Bu ultrashort-acting beta-adrenergic antagonist to isoprenaline-induced tachycardia — comparison with esmolol, Acta Vet. Brno, 2004, 73, 171–179 Cecchetti V., Schiaffella F., Tabarrini O., Fravolini A., (1,4-Benzothiazinyloxy)alkylpiperazine derivatives as potential antihypertensive agents, Bioorg. Med. Chem. Lett., 2000, 10, 465–468 Handzlik J., Maciąg D., Kubacka M., Mogilski Sz., Filipek B., Stadnicka K., et al., Synthesis, alpha 1-adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin, Bioorg. Med. Chem., 2008, 16, 5982–5998 Chiang Ch.-H., Chang T.-J., Lu D.-W., Lee A.-R., Intraocular pressure lower effects of novel arylpiperazine derivatives, J. Ocular Pharmacol. Ther., 1998, 14, 313–322 Caliendo G., Santagada V., Perissutti E., Fiorino F., Derivatives as 5HT1A receptor ligands-past and present, Curr. Med. Chem., 2005, 12, 1721–1753 Chilmonczyk Z., Mazgajska M., Iskra-Jopa J., Chojnacka-Wojcik E., Tatarczyńska E., Kłodzirska E., et al., Pharmacological properties and SAR of new 1,4-disubstituted piperazine derivatives with hypnotic-sedative activity, J. Pharm. Pharmacol., 2002, 54, 689–698 Di Santo R., Costi R., Artico M., Massa S., Ragno R., Marshall G.R., et al., Pharmacological properties and SAR of new 1,4-disubstituted piperazine derivatives with hypnotic-sedative activity, Bioorg. Med. Chem., 2002, 10, 2511–2526 Kimura M., Masuda T., Hamada K., Kawakatsu N., Kubota N., Mitani M., et al., Antioxidative activities of novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter, Bioorg. Med. Chem. Lett., 2004, 14, 4287–4290 Filosa R., Peduto A., de Caprariis P., Saturnino C., Festa M., Petrella A., et al., Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methylpiperazine, Eur. J. Med. Chem., 2007, 42, 293–306 Shaw Y.-J., Yang Y.-T., Garrison J.B., Kyprianou N., Chen Ch.-S., Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation, J. Med. Chem., 2004, 47, 4453–4462 Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., et al., Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J. Med. Chem., 2004, 47, 6658–6661 Stefańska J., Struga M., Tyski S., Kossakowski J., Dobosz M., Antimicrobial activity of 2,4-dihydro-[1,2,4]triazol-3-one derivatives, Pol. J. Microbiol., 2008, 57, 179–182 Foroumadi A., Emami S., Hassanzadeh A., Rajaee M., Sokhanvar K., Moshafi M.H., et al., Synthesis and antibacterial activity of N-(5-benzylthio-1,3,4-thiadiazol-2-yl) and N-(5-benzylsulfonyl-1,3,4-thiadiazol-2-yl)piperazinyl quinolone derivatives, Bioorg. Med. Chem. Lett., 2005, 15, 4488–4492 Richter S., Parolin C., Palumbo M., Palu G., Antiviral properties of quinolone-based drugs, Curr. Drug Target Infect Disord., 2004, 4, 111–116 Hadizadeh F., Mehrparvar A., Synthesis of some new 1-[2-(alkylthio-1-benzyl-5-imidazolyl) carbonyl]-4-[3-(isopropylamino)-2-pydridyl] piperazines as anti-HIV, J. Sci. Isl. Rep. Iran., 2004, 15, 131–134 Pinna G.A., Loriga G., Murineddu G., Grella G., Mura M., Vargiu L., et al., Synthesis and anti-HIV-1 activity of new delavirdine analogues carrying arylpyrrole moieties, Chem. Pharm. Bull., 2001, 49, 1406–1411 Kossakowski J., Wojciechowska A., Synthesis of oxiran-2-ylmethyl and oxiran-2-ylmethoxy derivatives of some 4-azatricyclo[5.2.1.0(2,6)]dec-8-ene-3,5-diones as potential beta-adrenolytics, Acta Pol. Pharm., 2006, 63, 485–490 Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Disc Susceptibility Tests; Approved Standard M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2006 Clinical and Laboratory Standards Institute, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2006 Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., et al., Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds, J. Virol. Meth, 1988, 20, 309–321